StreetInsider.com News Articles

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159976.html

Guggenheim says investors should own this biotech stock

Sun, 27 Sep 2026 04:00:00 -0400

Analysts at Guggenheim expressed optimism about the outlook of one biotech stock after it announced highly positive top-line results for two Phase III studies of its lead program.

Celldex Therapeutics (NYSE: CLDX), rated Buy at the firm with a price target of $100, is a Top Pick at Guggenheim, and last week’s results from Phase III CSU (chronic spontaneous urticaria) studies of barzolvolimab reinforce this view.

Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for diseases driven by the immune system, with a particular emphasis on mast-cell biology. Its lead program, barzolvolimab, targets KIT (a receptor tyrosine kinase

Guggenheim says investors should own this biotech stock

Sun, 27 Sep 2026 04:00:00 -0400

Analysts at Guggenheim expressed optimism about the outlook of one biotech stock after it announced highly positive top-line results for two Phase III studies of its lead program.

Celldex Therapeutics (CLDX) PT Raised to $57 at Morgan Stanley

Wed, 23 Sep 2026 06:20:40 -0400

(Updated - September 23, 2026 6:20 AM EDT)

Morgan Stanley analyst Judah Frommer raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $57.00 (from $50.00) while maintaining a Overweight rating.

The analyst comments "Next steps. CLDX expects to share full 24-week data from EMBARQ-CSU in February 2027 (note that today's release included 24-week safety and Week 24 data for UAS7=0 rates, in addition to Week 12 efficacy data). The company also reiterated plans for a BLA submission in 2027. On the call, management indicated potentially taking both dose regimens forward (150mg Q4W and 300mg Q8W, along with their loading doses) to

Celldex Therapeutics (CLDX) PT Raised to $57 at Morgan Stanley

Wed, 23 Sep 2026 06:20:40 -0400

(Updated - September 23, 2026 6:20 AM EDT)

Morgan Stanley analyst Judah Frommer raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $57.00 (from $50.00) while maintaining a Overweight rating.

Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)

Tue, 22 Sep 2026 10:21:00 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Celldex Therapeutics (NASDAQ: CLDX).

The analyst comments "CLDX reported positive topline results across both Ph3 CSU studies. Barzolvolimab showed a ~10pt placebo-adj UAS7 change from baseline at week 12--a slight regression from the Ph2 (~13pt), though is still better than Rhapsido at ~7pts, while UAS7=0 results of ~32% (pbo-adjusted) also support best-in-disease activity--also clearly observed in the Omalizumab-refractory population. That said, while a positive efficacy outcome was largely expected, the key debate remains focused on safety and implications for positioning in the market. Two cases of anaphylaxis were

Form 8-K Celldex Therapeutics, For: Sep 22

Tue, 22 Sep 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260922/27087469.html

Celldex's barzolvolimab meets Phase 3 endpoints in chronic hives trial

Tue, 22 Sep 2026 06:58:20 -0400

Celldex Therapeutics (NASDAQ: CLDX) reported positive topline results from two Phase 3 trials of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines, according to a company press release.

The EMBARQ-CSU1 and EMBARQ-CSU2 studies, which enrolled a combined 1,939 patients, met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, as well as all key secondary endpoints. Both doses tested — 150 mg every four weeks and 300 mg every eight weeks — showed statistically significant reductions in UAS7 compared to placebo (p<.00001) in both trials.

Complete response

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Tue, 22 Sep 2026 06:58:00 -0400

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSU
EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups
Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema
Efficacy sustained or deepened from weeks 12 to 24
Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies
Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027
Company to host webcast today at 8:00 am

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Tue, 22 Sep 2026 06:58:00 -0400

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSU
EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups
Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema
Efficacy sustained or deepened from weeks 12 to 24
Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies
Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027
Company to host webcast today at 8:00 am

Celldex Therapeutics (CLDX) PT Raised to $50 at Morgan Stanley

Thu, 10 Sep 2026 07:59:20 -0400
Morgan Stanley analyst Judah Frommer raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $46.00) while maintaining a Overweight rating.

Celldex to Present at Upcoming Investor Conference

Tue, 08 Sep 2026 16:01:00 -0400

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based

Celldex to Present at Upcoming Investor Conference

Tue, 08 Sep 2026 16:01:00 -0400

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP

Fri, 14 Aug 2026 12:09:00 -0400
si-local-file:///var/storage/secattach/20260814/26927634.html

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP

Fri, 14 Aug 2026 12:09:00 -0400
si-local-file:///var/storage/secattach/20260814/26927634.html

Form SCHEDULE 13G Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400
si-local-file:///var/storage/secattach/20260814/26926600.html

Form SCHEDULE 13G Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400
si-local-file:///var/storage/secattach/20260814/26926600.html

Celldex Therapeutics (CLDX) PT Raised to $53 at Barclays

Fri, 07 Aug 2026 04:53:38 -0400
Barclays analyst Etzer Darout raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $53.00 (from $48.00) while maintaining a Overweight rating.

Form 10-Q Celldex Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260806/26883737.html

Form 10-Q Celldex Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260806/26883737.html

Celldex (CLDX) Tops Q2 EPS by 12c

Thu, 06 Aug 2026 16:05:09 -0400

Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.94), $0.12 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $22 thousand versus the consensus estimate of $802.64 thousand.
For earnings history and earnings-related data on Celldex (CLDX) click here.

Form 8-K Celldex Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260806/26883313.html

Form 8-K Celldex Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260806/26883313.html

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:01:00 -0400

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026
Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing

HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:01:00 -0400

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026
Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing

HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter